Small Molecule Therapeutics for Schizophrenia (2015)

Sylvain Celanire, Sonia Poli

1. Antipsychotics and the Dopamine–Serotonin Connection
Bart A. Ellenbroek and Andrea M. Cesura

2. GlyT-1 Inhibitors: From Hits to Clinical Candidates
Roderick A. Porter and Lee A. Dawson

3. Metabotropic Glutamate Receptor 2 Activators
Jose´ M. Cid, Andre´s A. Trabanco, and Hilde Lavreysen

4. Activation of the mGlu5 Receptor for the Treatment of Schizophrenia and Cognitive-Deficit-Associated Disorders
Theresa Williams, Marlene A. Jacobson, Mikhail Kalinichev, and Jean-Philippe Rocher

5. Muscarinic Acetylcholine Receptor Activators
Takaaki Sumiyoshi and Takeshi Enomoto

6. Nicotinic Acetylcholine Receptor Modulators
Anatoly Mazurov and Daniel Yohannes

7. The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia
Jamison B. Tuttle and Bethany L. Kormos

Index